Business Context and Reporting Period
Company: Amphastar Pharmaceuticals, Inc. (AMPH)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Amphastar is a bio-pharmaceutical company focused on developing, manufacturing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. The company operates as a single reportable segment (pharmaceutical products) following the integration of its BAQSIMI® acquisition. Key products include BAQSIMI® (glucagon nasal powder), Primatene MIST®, glucagon, epinephrine, and enoxaparin.
Key Financial Metrics
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Net Revenues | $732.0 million | $644.4 million | +14% |
| Gross Profit | $373.9 million | $351.1 million | +6% |
| Gross Margin | 51% | 54% | -300 bps |
| Net Income | $159.5 million | $137.5 million | +16% |
| Diluted EPS | $3.06 | $2.60 | +18% |
| Operating Cash Flow | $213.4 million | $183.5 million | +16% |
| Total Debt | $601.9 million | $590.0 million | +2% |
| Working Capital | $360.3 million | $264.2 million | +36% |
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by the full-year contribution of BAQSIMI® ($126.9 million in 2024 vs. $0 in 2023 product revenue) and increased sales of Primatene MIST® (+14%) and epinephrine (+15%).
- Revenue Recognition Shift: In 2024, the company transitioned from recognizing BAQSIMI® sales on a net basis (royalty-like) under a Transition Service Agreement (TSA) with Eli Lilly to recognizing gross revenues as it assumed distribution responsibilities. This shift increased reported revenue but lowered gross margins compared to the prior year.
- Product Declines: Sales of enoxaparin (-31%), naloxone (-17%), and glucagon (-5%) declined due to competition, market shifts to ready-to-use products, and unit volume decreases.
- Expense Trends: Selling, distribution, and marketing expenses increased 31% due to BAQSIMI® expansion. Research and development expenses remained flat ($73.9 million) as increased FDA fees and salaries were offset by lower clinical trial costs.
- Debt Structure: The company repaid a mortgage loan with East West Bank in June 2024 and entered into a new syndicated line of credit with ICBC Bank in China ($18.4 million outstanding).
Guidance, Outlook, and Risks
Outlook and Strategy:
- BAQSIMI® Integration: The TSA with Eli Lilly concluded on January 1, 2025. Amphastar now fully manages the supply chain and distribution for BAQSIMI® globally.
- Pipeline: The company is advancing over 20 product candidates, including biosimilar insulin products (AMP-004, AMP-005, AMP-025) and proprietary intranasal epinephrine.
- Capital Allocation: The company continues its share repurchase program ($85.5 million spent in 2024) and anticipates significant capital expenditures for facility expansions in the U.S. and China.
Key Risks and Contingencies:
- Supply Chain Concentration: Reliance on single-source suppliers for certain APIs and raw materials, including heparin for enoxaparin. Disruptions could halt production.
- Regulatory and Environmental: The AIM Act mandates reductions in hydrofluorocarbons (HFCs), impacting Primatene MIST® and inhalation pipeline assets. FDA approval timelines for new products remain uncertain.
- Debt Obligations: Significant indebtedness ($601.9 million) includes a $250 million term loan and $345 million in 2029 Convertible Notes. Covenants restrict dividends and additional indebtedness.
- Legal Proceedings: Ongoing patent litigation regarding Albuterol (settled in Jan 2025 for $2.0 million) and employment-related PAGA claims.
Investor Verification Checklist
- BAQSIMI® Milestone Payments: Verify the potential for up to $575 million in contingent milestone payments to Eli Lilly based on future net sales targets.
- Enoxaparin Inventory Valuation: Review the $7.4 million charge taken in 2024 to adjust enoxaparin inventory to net realizable value due to competitive pricing pressures.
- Convertible Note Conversion: Assess the dilution risk associated with the $345 million 2.00% Convertible Notes due 2029, which may be settled in cash or stock.
- China Operations: Evaluate risks related to the Nanjing facility, including geopolitical tensions, tariffs (10% additional tariff on Chinese imports effective Feb 2025), and regulatory compliance.
- Share Repurchase Program: Confirm the remaining authorization ($50.0 million available as of Dec 31, 2024) and the company's commitment to offsetting dilution.